Laura Shawver, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 230,692 shares at $4.58 ($1.2M) on 2022-11-09, disclosed to the SEC on 2023-05-10.
Scheduled sale ($1.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.58 | 43,896 | $201K | 16.6% |
| 2 | $4.58 | 43,896 | $201K | 16.6% |
| 3 | $6.16 | 57,100 | $352K | 29.1% |
| 4 | $5.31 | 42,900 | $228K | 18.8% |
| 5 | $5.31 | 42,900 | $228K | 18.8% |
| Total | $5.24 avg | 230,692 |
| $1.2M |
| 100% |
| Filing → |
| SPRY | SELL | 2025-02-04 | $616K | — | Filing → |
| SPRY | SELL | 2025-01-07 | $555K | — | Filing → |
| SPRY | SELL | 2024-12-04 | $5.2M | — | Filing → |